Abstract
The primary goal of cancer vaccines is to elicit tumor-specific cytotoxic T lymphocytes (CTL) capable of eradicating established tumors and preventing/eradicating their metastatic spread. CpG oligonucleotides (CpG ODN) activate and support the maturation of immune cells, including plasmacytoid dendritic cells and B lymphocytes, that express Toll-like receptor 9 (TLR9) and are capable of presenting tumor antigens to T cells. Thus, CpG ODN are effective vaccine adjuvants. The adjuvant activity of CpG ODN is improved by maintaining them in close physical and temporal proximity to the co-administered vaccine antigen. This work describes a method of chemically conjugating CpG ODN to antigens and/or cancer cells that improve the resulting CTL response.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Greten TF, Jaffee EM (1999) Cancer vaccines. J Clin Oncol 17:1047–1060
Lollini PL et al (2006) Vaccines for tumour prevention. Nat Res Cancer 6:204–216
Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4:401–411
Schijns VE, Lavelle EC (2011) Trends in vaccine adjuvants. Expert Rev Vaccines 10:539–550
Chiang CL et al (2011) Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 30:150–182
Klebanoff CA et al (2011) Therapeutic cancer vaccines: are we there yet? Immunol Rev 239:27–44
Krieg AM et al (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–548
Hemmi H et al (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740–745
Takeshita F et al (2001) Cutting Edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167:3555–3558
Shirota H et al (2000) Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxy-nucleotides as a novel antigen-specific immunomodulator. J Immunol 164:5575–5582
Tighe H et al (2000) Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 30:1939–1947
Heit A et al (2005) Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol 174:4373–4380
Shirota H et al (2001) Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 167:66–74
Sano K et al (2003) Oligodeoxy-nucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner. J Immunol 170:2367–2373
Shirota H, Klinman DM (2011) CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunol Immunother 60:659–669
Acknowledgement
This research was supported by the Intramural Research Program of the NIH, National Cancer Institute.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Shirota, H., Klinman, D.M. (2014). TLR-9 Agonist Immunostimulatory Sequence Adjuvants Linked to Cancer Antigens. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_27
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0345-0_27
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0344-3
Online ISBN: 978-1-4939-0345-0
eBook Packages: Springer Protocols